Hospital
Pomona Valley Hospital Medical Center
Pomona Valley Hospital Medical Center was paid $58.85M by Medicaid between Jan 2018 and Dec 2024, across 411 billing codes. Its largest line is 0450, Emergency room services — 12% of everything it billed.
33Billing provider infoPOMONA VALLEY HOSPITAL MEDICAL CENTER
POMONA, CA 91767
POMONA, CA 91767
33aNPI1407813660assigned 04/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$58.85M
24GClaims2,125,594
24DCodes billed411
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#52 of 410
Median peer was paid$6.90M
This provider vs. median8.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 298,310 | $7.65M | |
| 2019 | 278,969 | $6.90M | |
| 2020 | 237,602 | $5.77M | |
| 2021 | 286,163 | $7.69M | |
| 2022 | 330,658 | $10.39M | |
| 2023 | 372,568 | $10.91M | |
| 2024incomplete | 321,324 | $9.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 12% | 174,462 | 153,882 | $7.32M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.6% | 7,323 | 7,172 | $2.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 34,184 | 14,037 | $2.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.3% | 33,961 | 31,188 | $1.95M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 18,605 | 18,020 | $1.88M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 12,017 | 11,624 | $1.84M |
| Z7502 | 3.1% | 47,923 | 47,435 | $1.80M | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.4% | 22,146 | 9,325 | $1.40M |
| J3490 | Unclassified drugs | 1.8% | 60,524 | 33,297 | $1.06M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 8,709 | 8,351 | $990K |
| 0360 | 1.5% | 10,092 | 5,809 | $911K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 42,765 | 39,720 | $879K |
399 more codes
| 80053 | Comprehensive metabolic panel | 1.5% | 80,084 | $875K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 1.2% | 3,899 | $734K |
| Z9725 | 1.1% | 15,405 | $663K | |
| 85027 | 1.0% | 98,940 | $610K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.0% | 653 | $593K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13,923 | $579K |
| 99221 | <1% | 4,145 | $575K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,650 | $559K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,432 | $556K |
| 0949 | <1% | 17,278 | $538K | |
| 99285 | Emergency room visit (most serious) | <1% | 2,516 | $527K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 135 | $514K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,300 | $514K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 7,928 | $505K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,094 | $496K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,689 | $458K |
| 99499 | <1% | 3,919 | $449K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,831 | $431K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,064 | $431K |
| 99199 | Unlisted special service, procedure or report | <1% | 10,486 | $426K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,220 | $417K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,015 | $413K |
| 93975 | <1% | 2,939 | $407K | |
| 71045 | Radiologic examination, chest; single view | <1% | 38,707 | $404K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,787 | $392K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,612 | $391K |
| 99284 | Emergency room visit (serious) | <1% | 4,297 | $388K |
| 99070 | <1% | 47,950 | $366K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,487 | $366K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,101 | $363K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 9,954 | $362K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,647 | $361K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18,386 | $354K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,162 | $340K |
| Z7500 | <1% | 9,955 | $338K | |
| 97763 | <1% | 4,156 | $334K | |
| 97139 | <1% | 8,994 | $328K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,353 | $315K |
| 76830 | Ultrasound, transvaginal | <1% | 7,831 | $312K |
| 99234 | <1% | 9,065 | $308K | |
| 59025 | Fetal non-stress test | <1% | 15,135 | $307K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,847 | $307K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,909 | $304K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 8,298 | $304K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,394 | $295K |
| 76801 | <1% | 6,736 | $283K | |
| Q3014 | Telehealth originating site facility fee | <1% | 11,952 | $280K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,912 | $270K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,969 | $269K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,154 | $268K |
| 84484 | <1% | 29,029 | $263K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,372 | $255K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,952 | $253K |
| 97161 | <1% | 5,404 | $244K | |
| 93971 | <1% | 3,111 | $239K | |
| 0750 | <1% | 2,373 | $234K | |
| 83690 | <1% | 33,288 | $209K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,726 | $205K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,116 | $201K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,666 | $196K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27,276 | $187K |
| 92523 | <1% | 2,129 | $183K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,790 | $177K |
| 0710 | <1% | 7,741 | $175K | |
| Z4300 | <1% | 1,666 | $172K | |
| 97799 | <1% | 2,991 | $165K | |
| 70496 | <1% | 1,154 | $165K | |
| Z7610 | <1% | 16,389 | $165K | |
| 93970 | <1% | 1,288 | $158K | |
| 0250 | <1% | 25,531 | $156K | |
| 76641 | <1% | 3,743 | $156K | |
| 84702 | <1% | 12,234 | $150K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,565 | $150K |
| 93976 | <1% | 1,332 | $150K | |
| 97802 | <1% | 1,956 | $149K | |
| 0270 | <1% | 23,689 | $148K | |
| 83880 | <1% | 8,187 | $145K | |
| 0762 | <1% | 3,086 | $140K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,328 | $139K |
| 70498 | <1% | 1,228 | $139K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 92 | $139K |
| 72141 | <1% | 831 | $137K | |
| 81003 | <1% | 54,730 | $137K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,713 | $135K |
| 71250 | <1% | 1,451 | $135K | |
| 0301 | <1% | 2,890 | $128K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,977 | $125K |
| 95811 | <1% | 544 | $124K | |
| 96367 | <1% | 3,282 | $118K | |
| 70486 | <1% | 1,206 | $118K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,354 | $116K |
| 96112 | <1% | 739 | $114K | |
| 83605 | <1% | 11,632 | $112K | |
| 76770 | <1% | 2,629 | $111K | |
| 73630 | <1% | 7,198 | $109K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 492 | $107K |
| 82948 | <1% | 17,504 | $101K | |
| 72100 | <1% | 4,812 | $100K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,002 | $99K |
| 77066 | Tomosynthesis, mammo | <1% | 1,555 | $97K |
| 73030 | <1% | 5,818 | $97K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 566 | $95K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,157 | $93K |
| 73130 | <1% | 5,223 | $91K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 18,828 | $91K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 235 | $89K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 2,984 | $89K |
| 99218 | <1% | 628 | $88K | |
| 73562 | <1% | 5,327 | $88K | |
| 73610 | <1% | 4,957 | $86K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,323 | $86K |
| 85730 | <1% | 15,924 | $86K | |
| G0378 | Hospital observation service, per hour | <1% | 1,238 | $81K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,074 | $80K |
| 86901 | <1% | 15,579 | $77K | |
| 84145 | <1% | 5,488 | $77K | |
| 0637 | <1% | 9,849 | $71K | |
| 93798 | <1% | 4,225 | $71K | |
| 77336 | <1% | 664 | $70K | |
| 73221 | <1% | 473 | $70K | |
| 84703 | <1% | 9,194 | $69K | |
| 90715 | <1% | 2,533 | $66K | |
| 85610 | <1% | 18,045 | $65K | |
| 86850 | <1% | 9,050 | $63K | |
| 81025 | <1% | 12,578 | $63K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,491 | $63K |
| 87040 | <1% | 5,079 | $61K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,099 | $61K |
| 87077 | <1% | 10,123 | $61K | |
| 85004 | <1% | 27,273 | $60K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,203 | $60K |
| 87631 | <1% | 1,265 | $59K | |
| 96417 | <1% | 1,895 | $58K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,322 | $57K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,285 | $56K |
| 86900 | <1% | 15,540 | $56K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 879 | $56K |
| 72040 | <1% | 2,873 | $56K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,786 | $56K |
| 73110 | <1% | 3,065 | $55K | |
| 0760 | <1% | 1,835 | $54K | |
| 73502 | <1% | 2,617 | $50K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,435 | $49K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,282 | $49K |
| 81001 | <1% | 12,883 | $49K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,477 | $47K |
| 76536 | <1% | 1,809 | $47K | |
| 76870 | <1% | 1,313 | $45K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,383 | $44K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,364 | $42K |
| 73560 | <1% | 3,755 | $42K | |
| 97010 | <1% | 2,107 | $41K | |
| 87653 | <1% | 1,713 | $41K | |
| 0121 | <1% | 12 | $40K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,149 | $39K |
| 83735 | <1% | 6,745 | $39K | |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | <1% | 23 | $39K |
| 97165 | <1% | 791 | $39K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,159 | $39K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 398 | $38K |
| 73590 | <1% | 2,253 | $37K | |
| 86140 | <1% | 6,803 | $34K | |
| 74022 | <1% | 1,164 | $34K | |
| 96415 | <1% | 1,285 | $33K | |
| 87186 | <1% | 4,645 | $32K | |
| 74018 | <1% | 2,230 | $31K | |
| 86923 | <1% | 470 | $30K | |
| 73070 | <1% | 1,825 | $29K | |
| 88304 | <1% | 1,723 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 803 | $29K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,671 | $29K |
| 73564 | <1% | 1,941 | $29K | |
| 73090 | <1% | 1,785 | $28K | |
| 77334 | <1% | 32 | $27K | |
| 72110 | <1% | 1,292 | $26K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 624 | $26K |
| 0257 | <1% | 5,763 | $25K | |
| 0510 | <1% | 919 | $24K | |
| 96111 | <1% | 223 | $24K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 674 | $24K |
| 0160 | <1% | 696 | $24K | |
| 96376 | <1% | 1,117 | $24K | |
| 12001 | <1% | 920 | $23K | |
| 97113 | <1% | 679 | $23K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,762 | $22K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,376 | $22K |
| 71101 | <1% | 744 | $21K | |
| 82550 | <1% | 3,224 | $21K | |
| 82803 | <1% | 1,496 | $21K | |
| 99152 | <1% | 733 | $21K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,367 | $21K |
| 72070 | <1% | 1,098 | $20K | |
| 85378 | <1% | 2,902 | $19K | |
| 0272 | <1% | 1,827 | $19K | |
| 87081 | <1% | 2,806 | $18K | |
| 81015 | <1% | 10,760 | $17K | |
| 0682 | <1% | 78 | $17K | |
| 73552 | <1% | 984 | $17K | |
| 84100 | <1% | 4,251 | $17K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 242 | $16K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 292 | $16K |
| 99217 | <1% | 551 | $15K | |
| 82010 | <1% | 2,038 | $15K | |
| 73080 | <1% | 827 | $14K | |
| 0761 | <1% | 327 | $14K | |
| 82375 | <1% | 1,495 | $14K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,989 | $14K |
| 80061 | Lipid panel | <1% | 1,641 | $14K |
| 0214 | <1% | 45 | $13K | |
| 73100 | <1% | 1,097 | $13K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 55 | $13K |
| Z4302 | <1% | 1,053 | $13K | |
| 85384 | <1% | 1,236 | $13K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 63 | $12K |
| 99224 | <1% | 199 | $12K | |
| 87184 | <1% | 1,876 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,451 | $11K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 542 | $11K |
| Z4307 | <1% | 450 | $11K | |
| 73060 | <1% | 728 | $11K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 277 | $11K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,790 | $11K |
| 73600 | <1% | 673 | $11K | |
| 88307 | <1% | 260 | $10K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,309 | $10K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,513 | $10K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,582 | $10K |
| 12011 | <1% | 597 | $10K | |
| 72170 | <1% | 626 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,204 | $10K |
| 94060 | <1% | 287 | $10K | |
| 82553 | <1% | 740 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 184 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,616 | $9K |
| 77290 | <1% | 32 | $9K | |
| 77080 | <1% | 701 | $9K | |
| 86592 | <1% | 1,838 | $9K | |
| 85007 | <1% | 4,655 | $9K | |
| 73521 | <1% | 537 | $9K | |
| 82731 | <1% | 105 | $9K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 913 | $9K |
| 73620 | <1% | 497 | $9K | |
| 94729 | <1% | 261 | $9K | |
| 29125 | <1% | 1,081 | $8K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 18 | $8K |
| 72050 | <1% | 479 | $8K | |
| 73140 | <1% | 618 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,965 | $8K |
| 82552 | <1% | 1,016 | $8K | |
| 82140 | <1% | 789 | $8K | |
| 85009 | <1% | 2,123 | $7K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 412 | $7K |
| 70491 | <1% | 55 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 102 | $7K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 150 | $7K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,969 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,831 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 112 | $6K |
| 94727 | <1% | 260 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 41 | $6K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 932 | $6K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 100 | $5K |
| 73120 | <1% | 555 | $5K | |
| 10060 | <1% | 237 | $5K | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 141 | $5K |
| 0410 | <1% | 273 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 383 | $5K |
| 74178 | <1% | 26 | $5K | |
| 96523 | <1% | 42 | $5K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 196 | $5K |
| 29515 | <1% | 686 | $5K | |
| 99225 | <1% | 87 | $5K | |
| 97116 | <1% | 647 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,741 | $4K |
| 85651 | <1% | 1,641 | $4K | |
| 12002 | <1% | 335 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,123 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,225 | $4K |
| 86703 | <1% | 433 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 114 | $4K |
| 97172 | <1% | 97 | $4K | |
| 0258 | <1% | 1,145 | $4K | |
| 80076 | <1% | 501 | $4K | |
| 84439 | <1% | 582 | $4K | |
| 0370 | <1% | 50 | $4K | |
| 71020 | <1% | 146 | $3K | |
| 0271 | <1% | 678 | $3K | |
| 70360 | <1% | 230 | $3K | |
| 96416 | <1% | 72 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 410 | $3K |
| 93880 | <1% | 31 | $3K | |
| 94664 | <1% | 328 | $3K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 77 | $3K |
| 75571 | <1% | 84 | $3K | |
| 87420 | <1% | 152 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 111 | $2K |
| 71010 | <1% | 144 | $2K | |
| 70547 | <1% | 13 | $2K | |
| 36600 | <1% | 703 | $2K | |
| 85576 | <1% | 298 | $2K | |
| 87070 | <1% | 158 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 80 | $2K |
| Z7514 | <1% | 31 | $2K | |
| 76937 | <1% | 69 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 1,382 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 647 | $2K |
| 49083 | <1% | 24 | $2K | |
| 82607 | <1% | 180 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 438 | $2K |
| 85008 | <1% | 2,095 | $2K | |
| 73000 | <1% | 91 | $1K | |
| X4303 | <1% | 22 | $1K | |
| 47562 | <1% | 12 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 80 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 269 | $1K |
| 0324 | <1% | 167 | $1K | |
| 93017 | <1% | 31 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $1K |
| 96368 | <1% | 86 | $1K | |
| 87340 | <1% | 174 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 370 | $1K |
| 88342 | <1% | 44 | $1K | |
| 92521 | <1% | 12 | $1K | |
| 27502 | <1% | 47 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 344 | $1K |
| 29505 | <1% | 105 | $1K | |
| 93925 | <1% | 16 | $990.33 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 28 | $946.41 |
| 87210 | <1% | 107 | $944.17 | |
| 82533 | <1% | 138 | $914.64 | |
| 88341 | <1% | 12 | $889.24 | |
| 58558 | <1% | 12 | $864.00 | |
| 0420 | <1% | 37 | $843.25 | |
| 97162 | <1% | 39 | $838.90 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 33 | $816.45 |
| 97152 | <1% | 16 | $799.52 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 167 | $753.74 |
| 29105 | <1% | 64 | $670.61 | |
| 87493 | <1% | 32 | $634.61 | |
| 84132 | <1% | 177 | $629.49 | |
| 86803 | <1% | 48 | $596.80 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 106 | $581.01 |
| 86870 | <1% | 13 | $562.84 | |
| 87205 | <1% | 109 | $549.47 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 15 | $504.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 30 | $496.40 |
| 87045 | <1% | 45 | $469.78 | |
| 85018 | <1% | 515 | $451.94 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 135 | $448.94 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 13 | $407.00 |
| 82150 | <1% | 97 | $380.97 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 56 | $370.30 |
| 71271 | <1% | 12 | $368.08 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 210 | $347.69 |
| 82728 | <1% | 25 | $322.06 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 225 | $315.19 |
| 29705 | <1% | 55 | $310.98 | |
| 27610 | <1% | 29 | $305.35 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 14 | $293.77 |
| 87425 | <1% | 29 | $280.87 | |
| 72081 | <1% | 12 | $279.10 | |
| 92611 | <1% | 13 | $264.60 | |
| 87075 | <1% | 18 | $238.18 | |
| 0300 | <1% | 461 | $235.43 | |
| 74000 | <1% | 15 | $225.82 | |
| 88302 | <1% | 12 | $225.04 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $216.00 |
| 87427 | <1% | 30 | $205.71 | |
| 97163 | <1% | 15 | $200.00 | |
| 29130 | <1% | 25 | $174.51 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14 | $168.84 |
| 74019 | <1% | 13 | $161.36 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 36 | $157.48 |
| 89055 | <1% | 43 | $138.65 | |
| 87209 | <1% | 14 | $137.42 | |
| 85347 | <1% | 47 | $114.31 | |
| 84156 | <1% | 42 | $112.52 | |
| 82330 | <1% | 13 | $108.46 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 31 | $101.05 |
| 87177 | <1% | 12 | $96.71 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 13 | $91.28 |
| 76882 | <1% | 24 | $79.66 | |
| 82746 | <1% | 12 | $77.11 | |
| 29075 | <1% | 14 | $64.80 | |
| 87046 | <1% | 33 | $62.81 | |
| 80164 | <1% | 12 | $55.84 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 76 | $49.65 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 75 | $45.18 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 14 | $39.24 |
| 82248 | <1% | 48 | $35.52 | |
| 85390 | <1% | 12 | $27.99 | |
| 0305 | <1% | 398 | $13.50 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 31 | $12.50 |
| 0307 | <1% | 18 | $2.80 | |
| 0730 | 0% | 85 | $0.00 | |
| 0302 | 0% | 42 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 359 | $0.00 |
| 0306 | 0% | 293 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESTER, JULI (EXECUTIVE DIRECTOR OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Pomona Valley Hospital Medical Center | Pomona, CA | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.